Table 1.

Summary of studies associating organoid sensitivity and patient response to approved systemic therapies.

Author, Year [Reference]	(Neo)Adjuvant and/or Metastatic Setting	Approved Systemic Therapies
		5-FU or Capecitabine	Irinotecan	Oxaliplatin	Cetuximab or Panitumumab	TAS-102	Regorafenib	Bevacizumab
		Anti-Metabolite	Topoisomerase Inhibitor	Platinum Compound	Anti-EGFR	Anti-Metabolite	Tyrosine Kinase Inhibitor	Anti-VEGF
Mo et al., 2022 [43]	Metastatic	n = 23	n = 10	n = 13
Hogenson et al., 2022 [36]	Metastatic	n = 2		n = 2	n = 2		n = 2
Lv et al., 2022 [37]	Neoadjuvant	n = 91	n = 107
Geevimaan et al., 2022 [20]	Adjuvant and Metastatic			n = 17
Yao et al., 2022 [21]	Adjuvant and Metastatic	n = 34		n = 34	n = 3			n = 8
Cho et al., 2022 [22]	Metastatic	n = 5	n = 2	n = 2	n = 1
Wang et al., 2021 [23]	Neoadjuvant and Metastatic	n = 66	n = 11	n = 55
Xu et al., 2021 [53]	Metastatic	n = 12		n = 12
Mauri et al., 2021 [46]	Metastatic	n = 1	n = 1	n = 1	n = 1
Narasimhan et al., 2020 [47]	Metastatic	n = 4		n = 4			n = 1
Arena et al., 2020 [45]	Metastatic			n = 3	n = 1
Yao et al., 2020 [24]	Neoadjuvant	n = 80	n = 66
Ooft et al., 2019 [25]	Metastatic	n = 32	n = 22	n = 10
Ganesh et al., 2019 [26]	Neoadjuvant and Metastatic	n = 7		n = 7
Pasch et al., 2019 [44]	Metastatic	n = 1		n = 1
Vlachogiannis et al., 2018 [27]	Metastatic				n = 4	n = 4	n = 3
	Positive association identified between organoid sensitivity and patient response
	Potential association between organoid sensitivity and patient response
	No association between organoid sensitivity and patient response
	n = Number of patients